Should Eliquis (apixaban) be held before catheter ablation for atrial fibrillation?

Eliquis Does NOT Need to Be Held for AF Ablation

Catheter ablation for atrial fibrillation should be performed with uninterrupted Eliquis (apixaban) anticoagulation, as this approach minimizes both thromboembolic and bleeding complications. 1

The Evidence-Based Approach

Uninterrupted Anticoagulation is Standard of Care

The most recent and authoritative guidelines strongly recommend performing AF ablation with uninterrupted oral anticoagulation 1. This represents a paradigm shift from older practices that interrupted anticoagulation with bridging therapy.

The 2020 Canadian guidelines explicitly state: "We recommend that catheter ablation procedures for AF be performed with uninterrupted OAC (Strong Recommendation; High-Quality Evidence)" 1. The 2024 European guidelines similarly recommend "uninterrupted oral anticoagulation is recommended in patients undergoing AF catheter ablation to prevent peri-procedural ischaemic stroke and thromboembolism" 2.

Why Uninterrupted Apixaban Works

Multiple randomized trials and large registries have demonstrated that:

• Uninterrupted DOACs (including apixaban) are superior to interrupted warfarin with bridging in terms of both safety and efficacy 1
• The AEIOU trial specifically studied apixaban and found that both uninterrupted and minimally interrupted apixaban (holding just 1 dose) resulted in very low rates of thromboembolic events (0%) and major bleeding (<2%) 3
• Large observational studies confirm that uninterrupted apixaban during AF ablation is safe, with no increased bleeding risk compared to warfarin 4

The Minimal Interruption Alternative

If your institution prefers a brief interruption, the 2018 European guidelines provide a reasonable middle ground: hold the last dose of apixaban 12 hours before the procedure 5. This approach:

• Maintains adequate anticoagulation (apixaban was typically given the evening before morning procedures)
• Allows for safer transseptal puncture in centers without routine intraprocedural imaging
• Has been validated in clinical trials showing equivalent safety to truly uninterrupted therapy 3

Practical Management Protocol

Before Ablation

• Continue apixaban through the morning of the procedure (truly uninterrupted), OR
• Hold 1 dose (last dose 12 hours before procedure) if institutional protocol prefers minimal interruption 5
• Ensure patient has been on therapeutic anticoagulation for at least 3-4 weeks before the procedure 1
• No bridging with heparin or LMWH is needed or recommended 1

During Ablation

• Administer intravenous heparin boluses to achieve activated clotting time (ACT) of 300-350 seconds (some guidelines suggest 350-400 seconds) 1, 5
• The ACT target is the same whether using uninterrupted apixaban or warfarin 5
• Note: Patients on apixaban may require slightly more heparin to reach target ACT 5

After Ablation

• Resume apixaban 3-5 hours after sheath removal once adequate hemostasis is established and pericardial effusion is ruled out 5
• The FDA label states apixaban "should be restarted after the surgical or other procedures as soon as adequate hemostasis has been established" 6
• Continue anticoagulation for at least 2 months post-ablation regardless of apparent procedural success 1

Critical Pitfalls to Avoid

Don't Use Bridging Therapy

The BRIDGE trial definitively showed that bridging anticoagulation with LMWH in AF patients undergoing procedures increases major bleeding (3.2% vs 1.3%) without reducing thromboembolism 1. This applies to AF ablation as well.

Don't Stop Anticoagulation Based on "Successful" Ablation

Long-term anticoagulation decisions should be based on stroke risk (CHA₂DS₂-VASc score), NOT on ablation success 1. Even after successful ablation:

• Asymptomatic AF recurrence is common
• Late AF recurrence can occur
• The CABANA trial showed no significant stroke reduction post-ablation 1

Don't Hold Apixaban for Extended Periods

Older 2014 guidelines suggested holding apixaban for 1-2 days before procedures with low bleeding risk and 2-3 days before high-risk procedures 7. This is outdated for AF ablation specifically—the newer evidence and guidelines support uninterrupted or minimally interrupted (1 dose) approaches 1, 2.

Special Considerations

Renal Function

Unlike dabigatran, apixaban dosing adjustments for procedures are not significantly affected by renal function 8. The standard approach applies across renal function levels.

Dose-Reduced Apixaban (2.5 mg BID)

Patients already on the reduced dose (2.5 mg BID) based on FDA criteria (≥2 of: age ≥80, weight ≤60 kg, creatinine ≥1.5 mg/dL) should continue this dose uninterrupted 6. The safety data for uninterrupted therapy applies to both standard and reduced doses.

Comparison to Other Approaches

The FDA label for apixaban states it "should be discontinued at least 48 hours prior to elective surgery or invasive procedures with a moderate or high risk of unacceptable or clinically significant bleeding" 6. However, this general surgical guidance does not apply to AF ablation, where specialty society guidelines based on ablation-specific trials take precedence and recommend uninterrupted therapy 1, 2.